1. Recommendations for clinical trial design in acute kidney injury from the 31st acute disease quality initiative consensus conference. A consensus statement.
- Author
-
Zarbock, Alexander, Forni, Lui, Koyner, Jay, Bell, Samira, Reis, Thiago, Meersch, Melanie, Bagshaw, Sean, Fuhmann, Dana, Liu, Kathleen, Pannu, Neesh, Arikan, Ayse, Angus, Derek, Duquette, DArcy, Goldstein, Stuart, Hoste, Eric, Joannidis, Michael, Jongs, Niels, Legrand, Matthieu, Mehta, Ravindra, Murray, Patrick, Nadim, Mitra, Ostermann, Marlies, Prowle, John, See, Emily, Selby, Nicholas, Shaw, Andrew, Srisawat, Nattachai, Ronco, Claudio, and Kellum, John
- Subjects
AKI ,Clinical trials ,Endpoints ,Enrichment ,Prevention ,Treatment ,Humans ,Acute Kidney Injury ,Research Design ,Clinical Trials as Topic ,Consensus ,Delphi Technique - Abstract
PURPOSE: Novel interventions for the prevention or treatment of acute kidney injury (AKI) are currently lacking. To facilitate the evaluation and adoption of new treatments, the use of the most appropriate design and endpoints for clinical trials in AKI is critical and yet there is little consensus regarding these issues. We aimed to develop recommendations on endpoints and trial design for studies of AKI prevention and treatment interventions based on existing data and expert consensus. METHODS: At the 31st Acute Disease Quality Initiative (ADQI) meeting, international experts in critical care, nephrology, involving adults and pediatrics, biostatistics and people with lived experience (PWLE) were assembled. We focused on four main areas: (1) patient enrichment strategies, (2) prevention and attenuation studies, (3) treatment studies, and (4) innovative trial designs of studies other than traditional (parallel arm or cluster) randomized controlled trials. Using a modified Delphi process, recommendations and consensus statements were developed based on existing data, with > 90% agreement among panel members required for final adoption. RESULTS: The panel developed 12 consensus statements for clinical trial endpoints, application of enrichment strategies where appropriate, and inclusion of PWLE to inform trial designs. Innovative trial designs were also considered. CONCLUSION: The current lack of specific therapy for prevention or treatment of AKI demands refinement of future clinical trial design. Here we report the consensus findings of the 31st ADQI group meeting which has attempted to address these issues including the use of predictive and prognostic enrichment strategies to enable appropriate patient selection.
- Published
- 2024